MOTS-c
MOTS-c: what it is, FDA status after the July 2026 advisory vote, and why the evidence is still preclinical.
Not FDA-approved · Evidence grade D · Reviewed
MOTS-c (Mitochondria-derived peptide). Peptide.
DNot FDA-approved. Evidence grade D: animal and lab data only.
What is MOTS-c?
MOTS-c is a peptide encoded in mitochondrial DNA. In mice it appears to mimic some effects of exercise.
Is MOTS-c FDA-approved?
Not approved for any use. An FDA advisory committee voted 7 to 5 in July 2026 to recommend it for the compounding list, for obesity and osteoporosis. The vote is advisory and changes nothing until FDA completes rulemaking.
What does the evidence show for MOTS-c?
Largely mechanistic and animal work. There is no established clinical role in people.
What are the known risks of MOTS-c?
Safety in people has not been established. The researcher who discovered it has objected publicly to people injecting black-market product.
How is MOTS-c measured?
Products sold online as "research use only" have no assurance of identity, dose or sterility. The calculator can do the arithmetic for any vial, but it cannot tell you what is actually in one.
Sources: AJMC: FDA panel backs 6 peptides for compounding; News Tribune: unregulated use of peptides. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.